Engineering Next-Generation Ipscs via Precise Genome Rewriting for Scalable T1d Cell Therapy

• High‑Throughput iPSC Screening: Leveraged GenoWriting™ to construct and screen a complete loss‑offunction iPSC library without residual gene expression.
• Enhanced Beta Cell Yields: Identified a double‑KO line that significantly boosted pancreatic beta cell differentiation efficiency.
• Rapid In Vivo Blood Glucose Control: Transplanting double‑KO cells into diabetic mice accelerated normoglycemia, improving T1D therapy scalability

Speakers:

Yasunori Aizawa

Chief Scientific Officer

Logomix,Inc.